67 terminated. 67 Phase 1, 22 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 67 | Terminated 67 |
| Phase 2 | 22 | Terminated 22 |
Follow Hematologic Neoplasms: new trials by email Literature Review of Hematologic Neoplasms trials Research Report on Hematologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers PF-08046032, Sasanlimab - Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 | Terminated | Pfizer | 6 | 2025-05-08 | 2026-05-08 |
| A Phase I Study of BR108 in Hematological Malignancies BR108 injection - Hematologic Malignancy | Phase 1 | Terminated | BioRay Pharmaceutical Co., Ltd. | 8 | 2023-03-18 | 2025-11-21 |
| SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma. SG2501 - Hematological Malignancy, Lymphoma | Phase 1 | Terminated | Hangzhou Sumgen Biotech Co., Ltd. | 2 | 2023-03-03 | 2025-03-18 |
| Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients Virus-specific Cytotoxic T-lymphocytes - Adenovirus Infection, BK Virus Infection | Phase 1 | Terminated | M.D. Anderson Cancer Center | 12 | 2023-01-06 | 2026-08-11 |
| A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies ATG-018 - Advanced Solid Tumors, Hematological Malignancies | Phase 1 | Terminated | Antengene Discovery Limited | 22 | 2022-07-08 | 2024-07-18 |
| PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies PRT1419, Azacitidine, Venetoclax - Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma | Phase 1 | Terminated | Prelude Therapeutics Incorporated | 21 | 2022-03-22 | 2024-01-31 |
| Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study Questionnaire Administration, Sotrovimab, Biospecimen Collection - COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 20 | 2022-01-25 | 2025-02-13 |
| Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 Omacetaxine Mepesuccinate, Venetoclax - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Biphenotypic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 24 | 2021-12-17 | 2025-11-03 |
| A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma EMB-06 - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Shanghai EpimAb Biotherapeutics Co., Ltd. | 40 | 2021-05-20 | 2025-05-28 |
| DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia DS-1594b, Azacitidine, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 17 | 2021-03-25 | 2025-05-23 |
| Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases Bintrafusp Alfa, Pimasertib, Quality-of-Life Assessment - Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 8 | 2021-01-15 | 2026-03-18 |
| A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms TAS1553 - Acute Myeloid Leukemia, Myeloproliferative Neoplasm | Phase 1 | Terminated | Astex Pharmaceuticals, Inc. | 20 | 2020-12-21 | 2024-08-02 |
| Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients Recombinant Interferon Alfa-2b, Rintatolimod - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 1 / Phase 2 | Terminated | Roswell Park Cancer Institute | 4 | 2020-11-17 | 2026-01-13 |
| Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies ATG-017, ATG-017+Nivolumab - Solid Tumor, Hematological Malignancy | Phase 1 | Terminated | Antengene Therapeutics Limited | 36 | 2020-08-15 | 2024-07-23 |
| A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers ABBV-184 - Acute Myeloid Leukemia (AML), Non Small Cell Lung Cancer | Phase 1 | Terminated | AbbVie | 14 | 2020-05-05 | 2022-09-08 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Natural Killer Cell (CYNK-001) Infusions in Adults with AML CYNK-001 - Leukemia, Leukemia, Myeloid | Phase 1 | Terminated | Celularity Incorporated | 27 | 2020-03-12 | 2024-12-12 |
| Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. MB-102, Fludarabine, Cyclophosphamide - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 1 / Phase 2 | Terminated | Mustang Bio | 3 | 2020-02-17 | 2024-07-22 |
| A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors AZD0466 - Advanced Solid Tumors, Lymphoma | Phase 1 | Terminated | AstraZeneca | 9 | 2019-12-16 | 2023-08-02 |
| Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy IMM01 - Hematologic Malignancy | Phase 1 | Terminated | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 73 | 2019-11-19 | 2023-05-16 |
Showing 20 of 67. Sign in to see all of them.
Leukemia, Myeloid, Acute (20) · Myelodysplastic Syndromes (14) · Multiple Myeloma (13) · Leukemia, Lymphocytic, Chronic, B-Cell (11) · Lymphoma, Non-Hodgkin (11) · Primary Myelofibrosis (11) · Hodgkin Disease (10) · Lymphoma (10) · Myeloproliferative Disorders (9) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (9) · Leukemia (8) · Leukemia, Myelomonocytic, Chronic (8) · Polycythemia Vera (8) · Recurrence (8)
Hemic and Lymphatic Diseases (67) · Neoplasms by Site (67) · Hematologic Diseases (66) · Neoplasms (60) · Neoplasms by Histologic Type (36) · Immune System Diseases (28) · Immunoproliferative Disorders (27) · Lymphoproliferative Disorders (27) · Lymphatic Diseases (25) · Pathologic Processes (24) · Pathological Conditions, Signs and Symptoms (24) · Bone Marrow Diseases (23) · Disease Attributes (20) · Leukemia (20) · Leukemia, Myeloid (20)
Azacitidine (5) · fludarabine (5) · Cytarabine (4) · Nivolumab (4) · fludarabine phosphate (4) · venetoclax (4) · Cyclophosphamide (3) · Leucovorin (3) · AP 1903 reagent (2) · Alemtuzumab (2) · Daunorubicin (2) · Methotrexate (2) · Panobinostat (2) · Rituximab (2) · Specimen Handling (2)
M.D. Anderson Cancer Center (8) · Fred Hutchinson Cancer Center (3) · Gilead Sciences (3) · Incyte Corporation (3) · Bellicum Pharmaceuticals (2) · Exelixis (2) · National Cancer Institute (NCI) (2) · Pfizer (2) · Roswell Park Cancer Institute (2) · AbbVie (1) · Acrotech Biopharma Inc. (1) · Alliance for Clinical Trials in Oncology (1) · Antengene Discovery Limited (1) · Antengene Therapeutics Limited (1) · Astex Pharmaceuticals, Inc. (1)
United States (54) · Italy (5) · Canada (4) · Spain (4) · Australia (3) · China (3) · France (3) · Japan (3) · United Kingdom (3) · Israel (2) · Belarus (1) · Belgium (1) · Bulgaria (1) · Czechia (1) · Georgia (1)
Alpana Waghmare (1) · Amit Mahipal, M.D. (1) · Anupa Kudva, MD (1) · Chris Storgard, MD (1) · Courtney DiNardo, MD (1) · David Maloney (1) · David Stewart (1) · Dolores Grosso, DNP, CRNP (1)
PMID 23682558, PMID 28017967, PMID 29191916, PMID 29233821, PMID 30962222, PMID 31527168, PMID 33357452, PMID 33451977, PMID 35226739, PMID 36452492, PMID 36841672, PMID 36841758, PMID 36873868, PMID 36888930, PMID 38946484, PMID 39863139, PMID 40373381, PMID 40979071
2017 (3), 2016 (1), 2019 (1), P30CA016056 (1), P30CA016672 (1), P30CA072720 (1), P50CA100632 (1), R01CA114536 (1), U01CA062461 (1), U01CA062490 (1), U10CA031946 (1)